Description

Neoadjuvant chemotherapy has been shown to be equivalent to post-operative treatment for breast cancer, and allows for assessment of chemotherapy response. In a pilot trial of docetaxel (T) and capecitabine (X) neoadjuvant chemotherapy for Stage II/III BC, we assessed correlation between baseline gene expression and tumor response to treatment, and examined changes in gene expression associated with treatment. Patients received 4 cycles of TX. Tumor tissue obtained from Mammotome core biopsies pretreatment (BL) and post-Cycle 1 (C1) of TX was flash frozen and stored at -70C until processing. Gene expression analysis utilized Affymetrix HG-U133 Plus 2.0 GeneChip arrays. Statistical analysis was performed using BRB Array Tools after RMA normalization. Gene ontology (GO) pathway analysis used random variance t-tests with a significance level of p<0.005. For gene categories identified by GO pathway analysis as significant, expression levels of individual genes within those pathways were compared between classes using univariate t-tests; those genes with significance level of p<0.05 were reported.

Publication Title

Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.

Sample Metadata Fields

Specimen part, Time